Abstract 73P
Background
Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, highly invasive subtype of non-small cell lung cancer (NSCLC), with extremely poor prognosis. Immunotherapy and targeted therapy have become the mainstay of management of advanced NSCLC, however, have been scarcely reported in PSC. Herein, we conducted a multi-center, single-arm, phase II study to assess the efficacy and safety of camrelizumab plus famitinib as first-line treatment in pts with locally advanced or metastatic PSC.
Methods
In this study, treatment-naïve pts with histologically confirmed stage IIIB-IV PSC received camrelizumab (200 mg, i.v., q3w) plus famitinib (20 mg, orally, qd) until disease progression or intolerable toxicity. Simon's two-stage design was adopted, and 15 pts were planned to be enrolled in the first stage, with 3 or more responses observed to progress to the second stage. The primary endpoint was objective response rate (ORR) as per RECIST 1.1. Here, we reported the first-stage results.
Results
From August 4, 2021 to April 24, 2023, 15 pts were enrolled, with a median age of 64 years (range 45-72) and all being male (100%). Of the 15 pts, seven (46.7%) achieved a partial response and six (40.0%) had stable disease, with the confirmed ORR of 46.7% (95% CI 21.3-73.4) and disease control rate of 86.7% (95% CI 59.5-98.3). As of August 16, 2023, the median follow-up was 10.0 months (IQR 3.9-14.5). The median duration of response was 7.1 months (95% CI 5.0-NR), median progression-free survival was 7.8 months (95% CI 1.6-NR), and median overall survival was 18.2 months (95% CI 18.0-NR). The median number of camrelizumab cycles was 7.0 (range 1-19). Treatment-related adverse events (TRAEs) of any grade occurred in 15 pts (100.0%), with seven (46.7%) developing grade ≥3 TRAEs. The most common TRAEs were proteinuria (53.3%), hypertension, neutrophil count decreased, and platelet count decreased (46.7% each). Two pts had grade 5 AEs (unknown cause).
Conclusions
Camrelizumab plus famitinib as first-line therapy for PSC showed promising activity and acceptable safety during the first stage of this study. Enrollment for the second stage is ongoing.
Clinical trial identification
NCT04888429; May 17, 2021.
Legal entity responsible for the study
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display